

VIII – KEY PUBLICATIONS

Publications in peer-reviewed journals (underlined: First or last author is from my group; ***van den Broek**: van den Broek is last author).

van den Broek M, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz W, Melief C, Zinkernagel RM, Hengartner H. 1996. Tumor surveillance in perforin-deficient mice. *J. Exp. Med.* 184:1781-1791.

Probst HC, Lagnel J, Kollias G, ***van den Broek M**. 2003. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8⁺ T cell tolerance. *Immunity*.18:713-721.

Probst HC, McCoy K, Okazaki T, Honjo T, ***van den Broek M**. 2005. Resting dendritic cells induce peripheral CD8⁺ T cell tolerance in vivo through PD-1 and CTLA-4. *Nature Immunology* 6:280-286.

Keller AM, Schildknecht A, Xiao Y, **van den Broek M**, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8⁺ T cell tolerance and permits effective immunity. 2008. *Immunity* 29:1-13.

Schildknecht A, Brauer S, Brenner C, Lahl K, Schild HJ, Sparwasser T, Probst HC, ***van den Broek M**. FoxP3⁺ regulatory T cells essentially contribute to peripheral CD8⁺ T cell tolerance induced by steady-state dendritic cells. 2010. *Proc. Natl. Acad. Sci. USA* 107:199-203.

Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Behnke S, Prischy M, Knuth A, ***van den Broek M**. 2012. Radiotherapy promotes tumor-specific effector CD8⁺ T cells via DC activation. *J. Immunol.* 189:558-566.

Walter A, Schäfer M, Matter C, Urosevic.Maiwald M, Belloni B, Schönewolf N, Cecconi V, Kulig P, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, ***van den Broek M**. 2013. Aldara activates two independent immune defense pathways. *Nature Communications* 4:1560 doi: 10.1038/ncomms2566.

Braumüller H, Wieder T, Fischer S, Brenner E, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, **van den Broek M**, Häring HU, Handgretinger R, Quintanilla.Martinez L, Fend F, Schaller M, Schulze.Osthoff K, Röcken M. 2013. Th1 cell cytokines drive cancer into senescence. *Nature* 494:361-365.

Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, ***van den Broek M**. 2013. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. *Clinical Cancer Research* 19:4843-4853.

Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, ***van den Broek M**. 2015. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. *Immunity* 42:767-777.

Bransi A, Salgado O, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, ***van den Broek M**. 2015. Rational combination of immunotherapy with clinical efficacy in mice with advanced cancer. *Cancer Immunology Research* 3:1279-1288.

Curioni-Fontecedro A, Ickenberg C, Franzen D, Rogler G, Burger IA, ***van den Broek M**. 2017. Diffuse pseudoprogression in a patient with metastatic non-small cell lung cancer treated with Nivolumab. *Annals of Oncology* 28:2040-2041. DOI: 10.1093/annonc/mdx233

Silina K, Soltermann A, Movahedian Attar F, Casanova R, Uckelely Z, Thut H, Isajevs S, Cheng S, Curioni-Fontecedro A, Foukas P, Levesque M, Moch H, Liné A, ***van den Broek M**. 2018. Germinal

centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. *Cancer Res.* 78:1308-1320.

Zimmerli D, Cecconi V, Valenta T, Hausmann G, Cantù C, Restive G, Hafner J, Basler K, ***van den Broek M.** 2018. WNT-ligands control initiation and progression of human papilloma-virus-driven squamous cell carcinoma. *Oncogene*, 37:3753-3762.

Beffinger M, Tallón de Lara P, Tugues S, Vermeer M, Montagnolo Y, Ohs I, Cecconi V, Lucchiari G, Gagliardi A, Misljencevic N, Sutton J, Spörri R, Becher B, Gupta A, ***van den Broek M.** 2018. CSF1R-dependent monocytes are required for NK-mediated control of metastasis. *J Clin Invest insight*, 3(10):e97792.

Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Schmitt-Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel R, Tischler V, Soldini D, Moch H, *Curioni-Fontecedro A, ***van den Broek M.** 2018. Gemcitabine acts in synergy with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. *Clinical Cancer Res.* 24:6345-6354.

Schadt L, Sparano C, Schweiger N, Silina K, Cecconi V, Lucchiari G, Guggisberg E, Saba S, Nascakova Z, Barchet W, ***van den Broek M.** 2019. Cancer cell-intrinsic cGAS expression mediates tumor immunogenicity. *Cell Rep.* 29:1236-1248.

van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter JM, van Montfoort M, van Rooijen C, Peters D, Broeks A, van der Poel H, Bruining A, Lubeck Y, Sikorska K, Boellaard T, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, **van den Broek M**, Wessels L, Blank CU, van Rhijn BW, van der Heijden MS. 2020. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer. *Nature Med.* 26:1839-1844.

Tallón de Lara P, Castañón Cuadrado H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdínez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, ***van den Broek M.** 2021. CD39⁺PD-1⁺CD8⁺ T-cells mediate metastatic dormancy in breast cancer. *Nature Communications.* 12:769. doi.org/10.1038/s41467-021-21045-2.

Lelios I, Stifter SA, Cecconi V, Petrova E, Lutz M, Cansever D, Utz SG, Becher B, ***van den Broek M**, Greter M. 2021. Monocytes promote UV-induced epidermal carcinogenesis. *Eur. J. Immunol.* *In press.*

Ducimetière L, Lucchiari G, Litscher G, Nater M, Heeb L, Núñez N, Wyss L, Burri D, Vermeer M, Gschwend J, Moor A, Becher B, ***van den Broek M**, Tugues S. 2021. Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. Submitted. Available at BioRxiv <https://biorxiv.org/cgi/content/short/2020.07.17.206433v1>.